{
    "clinical_study": {
        "@rank": "53571", 
        "acronym": "SAFARI", 
        "arm_group": {
            "arm_group_label": "Rivaroxaban"
        }, 
        "brief_summary": {
            "textblock": "National, multicenter, prospective, observational, non-interventional study. The objective\n      is to determine if the switch from Vitamin K antagonists (VKA) to Xarelto in subjects\n      treated with VKA with issues for stroke prevention in non valvular atrial fibrillation is\n      associated with an improvement of the treatment satisfaction after 3 months. The treatment\n      satisfaction will be measured by the Anti Clot Treatment Scale (ACTS) score."
        }, 
        "brief_title": "Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Atrial Fibrillation", 
        "condition_browse": {
            "mesh_term": [
                "Atrial Fibrillation", 
                "Stroke"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female and male subjects \u2265 18 years of age with a diagnosis of non-valvular atrial\n             fibrillation\n\n          -  Who are treated with Vitamin K antagonists (VKA) with issues for at least the 4\n             previous weeks (issues are assessed on medical judgment)\n\n          -  Who start treatment with rivaroxaban to prevent stroke or non-CNS (central nervous\n             system) systemic embolism\n\n          -  With anticoagulation therapy planned for at least 6 months\n\n        Exclusion Criteria:\n\n          -  Contra indication to the use of Xarelto as described in the Summary of Product\n             Characteristics (SmPC); key contra indications are:\n\n               -  Hypersensitivity to the active substance or to any of the excipients listed in\n                  SmPC section 6.1.\n\n               -  Lesion or condition at significant risk of major bleeding\n\n               -  Concomitant treatment with any other anticoagulant agent\n\n               -  Clinically significant active bleeding\n\n               -  Hepatic disease associated with coagulopathy and clinically relevant bleeding\n                  risk including cirrhotic patients with Child Pugh B and C\n\n               -  Pregnancy and breast feeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients more than 18 years old, with a diagnosis of non-valvular atrial fibrillation,\n        treated to prevent stroke or non-central nervous system systemic embolism, who switch from\n        VKA to Xarelto due to issues with VKA"
            }
        }, 
        "enrollment": {
            "#text": "550", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01805531", 
            "org_study_id": "16398", 
            "secondary_id": "XA1213FR"
        }, 
        "intervention": {
            "arm_group_label": "Rivaroxaban", 
            "description": "20 mg po once daily, which is also the recommended maximum dose. In subjects with moderate creatinine clearance (30-49 ml/min), the dose 15 mg once daily is recommended.", 
            "intervention_name": "Rivaroxaban (Xarelto, BAY59-7939)", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "SF36 questionnaire", 
            "Anti Clot Treatment Scale", 
            "Satisfaction", 
            "Quality of Life", 
            "Rivaroxaban", 
            "Stroke prevention"
        ], 
        "lastchanged_date": "June 2, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Many locations", 
                    "country": "France"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_groups": "1", 
        "official_title": "Satisfaction and Quality of Life in Patients With a Diagnosis of Non Valvular Atrial Fibrillation Who Take Rivaroxaban for Stroke Prevention", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: none", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change of the Anti Clot Treatment Scale  (ACTS) score at 3 months compared with baseline score", 
            "safety_issue": "No", 
            "time_frame": "After 3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01805531"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change of ACTS score after 1 and 6 months of treatment", 
                "safety_issue": "No", 
                "time_frame": "After 1 and 6 months"
            }, 
            {
                "measure": "Continuation rate at 1, 3 and 6 months", 
                "safety_issue": "No", 
                "time_frame": "After 1, 3 and 6 months"
            }, 
            {
                "measure": "Change of SF36 score at 1, 3 and 6 months (health related quality of life determined by SF36 questionnaire)", 
                "safety_issue": "No", 
                "time_frame": "After 1, 3 and 6 months"
            }, 
            {
                "measure": "Physician's satisfaction at 1, 3 and 6 months assessed by a 5-point Likert scale response (\"very satisfied\", \"satisfied\", \"neutral\", \"unsatisfied\" or \"very unsatisfied\")", 
                "safety_issue": "No", 
                "time_frame": "After 1, 3 and 6 months"
            }, 
            {
                "measure": "Patient's compliance with VKA treatment at baseline and with Xarelto treatment at 1, 3 and 6 months assessed by the investigator as good (\u226580%), average (50-80%) or poor (<50%)", 
                "safety_issue": "No", 
                "time_frame": "After 1, 3 and 6 months"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "June 2014"
    }
}